Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | RORA | P35398 | 1/20 | 0.52 |
| ▸ | RORC | P51449 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.52 |
| ▸ | RORB | Q92753 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5466571 | 0.93 | LMNA (0.63) | LMNAKMT2AMEN1MAPTTP53 | |
| SCHEMBL5461627 | 0.91 | LMNA (0.62) | LMNAKMT2AMEN1MAPTTP53 | |
| SCHEMBL5468998 | 0.90 | LMNA (0.68) | LMNAKMT2AMEN1MAPTTP53 | |
| SCHEMBL5467360 | 0.88 | LMNA (0.70) | LMNAKMT2AMEN1MAPTTP53 | |
| SCHEMBL5469305 | 0.86 | LMNA (0.61) | LMNAKMT2AMEN1MAPTTP53 | |
| SCHEMBL5464507 | 0.85 | LMNA (0.73) | LMNAKMT2AMEN1MAPTTP53 | |
| SCHEMBL5467261 | 0.85 | LMNA (0.73) | LMNAKMT2AMEN1MAPTTP53 | |
| SCHEMBL5471844 | 0.85 | LMNA (0.71) | LMNAKMT2AMEN1MAPTTP53 | |
| SCHEMBL5467347 | 0.84 | LMNA (0.63) | LMNAKMT2AMEN1MAPTTP53 | |
| SCHEMBL5467377 | 0.84 | LMNA (0.68) | LMNAKMT2AMEN1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | LMNA 2632/4885KMT2A 1132/4885MEN1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.